Anthropic is drawing fresh attention after CEO Dario Amodei publicly defended his balance of warnings and optimism on AI and reiterated his view that the technology could help cure most human diseases within five to ten years. In a widely viewed August 15 exchange on X with investor Gavin Baker, Amodei argued that his public comments have not been disproportionately negative and pointed back to his 2024 essay "Machines of Loving Grace," which said AI could compress 50 to 100 years of biological progress into five to 10 years. The more consequential update was his timeline. Amodei said Anthropic is accelerating work in biology and medicine, expects major results in the coming years, and sees "some early glimmers in the coming months." He also acknowledged a central criticism of AI companies, including his own: that they have not yet delivered on many of their promises, and said public trust will not be won through marketing claims but through concrete outcomes. That stance comes as Anthropic pushes deeper into life sciences. The company launched Claude for Life Sciences in October last year, announced research partnerships with the Allen Institute and the Howard Hughes Medical Institute on February 2, and was reportedly set to acquire stealth biotech startup Coefficient Bio in a $400 million stock deal. Against that backdrop, prediction-market activity cited in the existing report showed odds of Anthropic reaching a $1.25 trillion valuation by year-end at 29.5%, up from 15% a week earlier, while investors watch for evidence that its biology strategy can produce measurable results.